Skip to main content
CSL Behring News)

Global Newsroom

Recent News Releases

 

Latest CSL News

Latest CSL News

CSL Committed to AZ COVID Vaccine
14 Oct 2021

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022

CSL Requires COVID-19 Vaccination
08 Oct 2021

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors

Applications Open for Fellowships
01 Jun 2021

$2.5 Million Funding Available to Australian Biomedical Researchers

CSL welcomes the Patent Box Policy
12 May 2021

New Patent Box policy will benefit domestic commercialisation of medical research

CSL welcomes domestic mRNA vaccine development
12 May 2021

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies

CSL Behring Announces Agreement with uniQure
06 May 2021

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

2020 RAI Awardees Announced
29 Apr 2021

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL

CSL’s Global Role in Battling COVID-19
02 Apr 2021

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

COVID-19 Update
02 Apr 2021

CSL continues to provide medicines to patients around the world.

Local Manufacturing of COVID-19 Vaccine Update
12 Feb 2021

CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards the end of March, subject to approval by the Therapeutic Goods Administration (TGA).

AUS Clinical Trial of Treatment for COVID19
31 Jan 2021

24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin

University of Oxford/AstraZeneca Vaccine Candidate
08 Nov 2020

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.

Media Contacts

Christina Hickie

CSL Limited
Senior Manager, Communications
Phone: +61 429 609 762

News & Press Release Archive